FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179090427> ?p ?o ?g. }

• W3179090427 endingPage "e003019" @default.
• W3179090427 startingPage "e003019" @default.
• W3179090427 abstract "Human telomerase reverse transcriptase (hTERT) is frequently classified as a 'universal' tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine cancer types.A phase 1 clinical trial was conducted in adult patients with no evidence of disease following definitive surgery and standard therapy, who were at high risk of relapse. Plasmid DNA encoding one of two hTERT variants (INO-1400 or INO-1401) with or without plasmid DNA encoding interleukin 12 (IL-12) (INO-9012) was delivered intramuscularly concurrent with the application of the CELLECTRA constant-current electroporation device 4 times across 12 weeks. Safety assessments and immune monitoring against native (germline, non-mutated, non-plasmid matched) hTERT antigen were performed. The largest cohort of patients enrolled had pancreatic cancer, allowing for additional targeted assessments for this tumor type.Of the 93 enrolled patients who received at least one dose, 88 had at least one adverse event; the majority were grade 1 or 2, related to injection site. At 18 months, 54.8% (51/93) patients were disease-free, with median disease-free survival (DFS) not reached by end of study. For patients with pancreatic cancer, the median DFS was 9 months, with 41.4% of these patients remaining disease-free at 18 months. hTERT immunotherapy induced a de novo cellular immune response or enhanced pre-existing cellular responses to native hTERT in 96% (88/92) of patients with various cancer types. Treatment with INO-1400/INO-1401±INO-9012 drove hTERT-specific IFN-γ production, generated hTERT-specific CD4+ and CD8+ T cells expressing the activation marker CD38, and induced hTERT-specific activated CD8 +CTLs as defined by cells expressing perforin and granzymes. The addition of plasmid IL-12 adjuvant elicited higher magnitudes of cellular responses including IFN-γ production, activated CD4+ and CD8+ T cells, and activated CD8+CTLs. In a subset analysis of pancreatic cancer patients, the presence of immunotherapy-induced activated CD8+ T cells expressing PD-1, granzymes and perforin correlated with survival.Plasmid DNA-encoded hTERT/IL-12 DNA immunotherapy was well-tolerated, immune responses were noted across all tumor types, and a specific CD8+ phenotype increased by the immunotherapy was significantly correlated with survival in patients with pancreatic cancer." @default.
• W3179090427 created "2021-07-19" @default.
• W3179090427 creator A5015377056 @default.
• W3179090427 creator A5015488396 @default.
• W3179090427 creator A5019734570 @default.
• W3179090427 creator A5023265367 @default.
• W3179090427 creator A5025867351 @default.
• W3179090427 creator A5032090717 @default.
• W3179090427 creator A5040750947 @default.
• W3179090427 creator A5044525694 @default.
• W3179090427 creator A5045028558 @default.
• W3179090427 creator A5050688181 @default.
• W3179090427 creator A5067843924 @default.
• W3179090427 creator A5067915183 @default.
• W3179090427 creator A5071608389 @default.
• W3179090427 creator A5072203753 @default.
• W3179090427 creator A5076663691 @default.
• W3179090427 creator A5079427446 @default.
• W3179090427 creator A5086781190 @default.
• W3179090427 date "2021-07-01" @default.
• W3179090427 modified "2023-10-13" @default.
• W3179090427 title "Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors" @default.
• W3179090427 cites W1539988689 @default.
• W3179090427 cites W1545398558 @default.
• W3179090427 cites W1973647796 @default.
• W3179090427 cites W1988424227 @default.
• W3179090427 cites W1995541635 @default.
• W3179090427 cites W1996814108 @default.
• W3179090427 cites W2000971601 @default.
• W3179090427 cites W2008495999 @default.
• W3179090427 cites W2016779153 @default.
• W3179090427 cites W2023245620 @default.
• W3179090427 cites W2030976397 @default.
• W3179090427 cites W2033488675 @default.
• W3179090427 cites W2042897772 @default.
• W3179090427 cites W2049757773 @default.
• W3179090427 cites W2064248337 @default.
• W3179090427 cites W2073541555 @default.
• W3179090427 cites W2090083872 @default.
• W3179090427 cites W2094056217 @default.
• W3179090427 cites W2120602190 @default.
• W3179090427 cites W2122476064 @default.
• W3179090427 cites W2133301992 @default.
• W3179090427 cites W2136293754 @default.
• W3179090427 cites W2149421090 @default.
• W3179090427 cites W2151237411 @default.
• W3179090427 cites W2152562488 @default.
• W3179090427 cites W2156946668 @default.
• W3179090427 cites W2415521374 @default.
• W3179090427 cites W2532791459 @default.
• W3179090427 cites W2588947843 @default.
• W3179090427 cites W2606935378 @default.
• W3179090427 cites W2766151412 @default.
• W3179090427 cites W2799739596 @default.
• W3179090427 cites W2937397727 @default.
• W3179090427 cites W2945080083 @default.
• W3179090427 cites W2975747611 @default.
• W3179090427 cites W3006147225 @default.
• W3179090427 cites W3037013420 @default.
• W3179090427 cites W3048851393 @default.
• W3179090427 cites W4250153617 @default.
• W3179090427 cites W97711432 @default.
• W3179090427 doi "https://doi.org/10.1136/jitc-2021-003019" @default.
• W3179090427 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8261871" @default.
• W3179090427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34230114" @default.
• W3179090427 hasPublicationYear "2021" @default.
• W3179090427 type Work @default.
• W3179090427 sameAs 3179090427 @default.
• W3179090427 citedByCount "13" @default.
• W3179090427 countsByYear W31790904272022 @default.
• W3179090427 countsByYear W31790904272023 @default.
• W3179090427 crossrefType "journal-article" @default.
• W3179090427 hasAuthorship W3179090427A5015377056 @default.
• W3179090427 hasAuthorship W3179090427A5015488396 @default.
• W3179090427 hasAuthorship W3179090427A5019734570 @default.
• W3179090427 hasAuthorship W3179090427A5023265367 @default.
• W3179090427 hasAuthorship W3179090427A5025867351 @default.
• W3179090427 hasAuthorship W3179090427A5032090717 @default.
• W3179090427 hasAuthorship W3179090427A5040750947 @default.
• W3179090427 hasAuthorship W3179090427A5044525694 @default.
• W3179090427 hasAuthorship W3179090427A5045028558 @default.
• W3179090427 hasAuthorship W3179090427A5050688181 @default.
• W3179090427 hasAuthorship W3179090427A5067843924 @default.
• W3179090427 hasAuthorship W3179090427A5067915183 @default.
• W3179090427 hasAuthorship W3179090427A5071608389 @default.
• W3179090427 hasAuthorship W3179090427A5072203753 @default.
• W3179090427 hasAuthorship W3179090427A5076663691 @default.
• W3179090427 hasAuthorship W3179090427A5079427446 @default.
• W3179090427 hasAuthorship W3179090427A5086781190 @default.
• W3179090427 hasBestOaLocation W31790904271 @default.
• W3179090427 hasConcept C104317684 @default.
• W3179090427 hasConcept C121608353 @default.
• W3179090427 hasConcept C125593758 @default.
• W3179090427 hasConcept C126322002 @default.
• W3179090427 hasConcept C143998085 @default.
• W3179090427 hasConcept C147483822 @default.
• W3179090427 hasConcept C197934379 @default.
• W3179090427 hasConcept C203014093 @default.

• next